Coverage
-
March 25, 2019
Myriad Genetics Inc. and its directors on Monday shook a proposed securities class action alleging a fraudulent billing of Medicare after a Utah federal judge ruled the suing investor failed to plead that the company's billing was illegal or even an outlier in the industry.
2 other articles on this case.
View all »